PT-141, Bremelanotide, and the Central Nervous System Approach to Sexual Wellness

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

The clinical landscape for sexual function pharmacology has been shaped, for the past quarter-century, by a single class of compounds: the phosphodiesterase type 5 (PDE5) inhibitors. Sildenafil, tadalafil, and vardenafil all act through the same mechanism. They increase nitric oxide-mediated vasodilation in peripheral tissue. The mechanism is well-understood, the drugs are widely prescribed, and the framework they established for thinking about sexual function pharmacology is essentially peripheral and vascular.

Bremelanotide, sold as Vyleesi and known in the research literature as PT-141, operates through a different pathway entirely. It acts in the central nervous system. It targets the melanocortin receptor family. It modifies the neural processing that precedes sexual arousal rather than the vascular events that follow it. The compound's mechanism opened a different conceptual category in sexual function pharmacology when it received FDA approval in 2019.

This article describes what PT-141 is, where the molecule came from, how it works, and where the current research and regulatory landscape sits.

The molecule and its origin

Bremelanotide is a synthetic cyclic heptapeptide. It is a structural analog of alpha-melanocyte-stimulating hormone, the endogenous peptide derived from proopiomelanocortin that signals through the melanocortin receptor system. The compound was developed by Palatin Technologies, which began its melanocortin research program in the 1990s with an initial focus on the pigmentation effects of melanocortin signaling, then extended into other physiological effects mediated by the receptor family.1

The compound's sexual function effects were identified during clinical testing of the closely related compound Melanotan II in the 1990s. Investigators noted that subjects in tanning studies reported sexual arousal effects unrelated to the compound's pigmentation activity. The observation triggered a program to develop a melanocortin receptor agonist with the sexual function effects but without the pigmentation activity. PT-141, the truncated cyclic peptide that resulted, retained the sexual function effects while showing reduced affinity for the melanocortin 1 receptor (the receptor associated with pigmentation effects).2

Mechanism

The melanocortin receptor family consists of five G-protein-coupled receptors (MC1R through MC5R), each with different tissue distributions and physiological effects. MC1R is expressed primarily on melanocytes and mediates pigmentation effects. MC3R and MC4R are expressed in the central nervous system, particularly in hypothalamic and limbic structures, and are associated with energy balance, food intake, and sexual function. MC5R is expressed in exocrine tissues. MC2R mediates adrenal corticosteroid responses.3

Bremelanotide is a non-selective melanocortin receptor agonist with relative preference for MC3R and MC4R. Its sexual function effects are believed to occur through MC4R activation in central nervous system structures involved in sexual arousal processing. The downstream neural circuitry includes regions of the hypothalamus and limbic system that integrate sensory, hormonal, and contextual inputs into the sexual response. The compound does not produce its effects through vascular mechanisms in peripheral tissue.4

The distinction between central and peripheral mechanisms is significant for understanding what the compound does and does not do. PDE5 inhibitors enhance the vascular response to sexual arousal but do not produce arousal in their absence. Bremelanotide acts upstream of the vascular response, on the neural circuits associated with the arousal itself. The two mechanisms can in principle be complementary, and they target different points in the physiological cascade.

The FDA approval history

Vyleesi (bremelanotide) received FDA approval in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the second approved drug for that indication, following flibanserin (Addyi), which works through serotonin receptor modulation. Vyleesi differs from flibanserin in that it is administered on-demand by subcutaneous injection (with an autoinjector pen) rather than as a daily oral medication.5

The approval was based on two phase III randomized controlled trials, RECONNECT-1 and RECONNECT-2, which together enrolled more than 1,200 premenopausal women with diagnosed HSDD. The primary endpoints were changes in measures of sexual desire and sexual-related distress over 24 weeks of treatment. The trials met their primary endpoints, with a magnitude of effect that the FDA determined justified approval for the indication.6

The compound's approval was significant in part because the FDA-approved pharmacology of female sexual function had been substantially narrower than the corresponding pharmacology for male erectile function. The melanocortin mechanism opened a different therapeutic approach to female sexual function that did not rely on hormonal modulation (the historic approach to female sexual dysfunction pharmacology) or on the peripheral vasodilatory mechanisms that had not translated well to the female anatomy in clinical trials.

Side effect profile

The Vyleesi label includes several notable side effect categories. The most common reported effects are nausea (reported by roughly 40 percent of subjects in the pivotal trials), flushing, headache, and injection-site reactions. The nausea is typically transient and most severe with the first administration.7

A more clinically relevant effect is the compound's vasoactive profile. Bremelanotide produces transient increases in blood pressure, typically peaking around 2 to 4 hours after administration. The Vyleesi label includes warnings about use in patients with cardiovascular conditions and contraindications for patients with uncontrolled hypertension. The vasoactive effect is consistent with the melanocortin receptor distribution in vascular smooth muscle.

A smaller fraction of subjects experience focal pigmentation changes (the residual MC1R activity, even reduced relative to Melanotan II, remains present). The effect is typically subtle and reversible but is a documented effect of repeated use.

Off-label use in men

Bremelanotide is not FDA-approved for use in men. Its clinical investigation in male erectile function has occurred but the development program for male approval was discontinued by Palatin Technologies in favor of the female HSDD indication. The mechanism, however, is not anatomically gender-specific. Melanocortin receptor activation in central nervous system circuits associated with sexual function produces effects in both sexes, and the published research on PT-141 includes studies in male subjects showing measurable changes in markers of sexual response.8

The off-label use of PT-141 in men proceeds under physician supervision when prescribed by a physician with a clinical rationale for the use. This is a legal off-label prescribing context similar to many other peptide and pharmaceutical compounds used off-label in integrative medicine practice. It is distinct from the research-chemical channel that distributes PT-141 outside any physician-patient-pharmacy relationship.

Regulatory status and compounding access

As an FDA-approved drug, bremelanotide is commercially available as Vyleesi by prescription. The compound is also available in 503A compounded preparations for off-label use under physician prescription, since compounding pharmacies may prepare custom medications using bulk drug substances that are the subject of FDA-approved drugs.9

This makes PT-141 one of a small set of peptides with multiple legitimate access pathways in the US: the FDA-approved branded drug (Vyleesi), the 503A compounded preparation, and the off-label prescription. The research-chemical channel that distributes the same compound without physician involvement operates outside any of those pathways and is the subject of the FDA enforcement attention discussed elsewhere in this collection.

What this article does not address

Several questions sit outside the scope of editorial review. Whether bremelanotide is appropriate for any specific person is a clinical question between that person and their prescribing physician. The compound's effect on any particular individual is not predictable from the clinical trial data, which describes population-level effects in defined subject groups. Comparative effectiveness against PDE5 inhibitors, or against the other approved HSDD treatment (flibanserin), is not a question that has been resolved in the published literature.

A summary for the reader

PT-141 is a melanocortin receptor agonist, FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Its mechanism is central rather than peripheral, distinguishing it conceptually and pharmacologically from the PDE5 inhibitor class that has dominated sexual function pharmacology for the past 25 years. The compound's published research base is substantial and includes both phase III approval trials and a wider literature on melanocortin signaling. Its safety profile is documented in the approved labeling. Its regulatory status is settled: FDA-approved for one indication, available off-label by prescription, available through 503A compounding, not available legally as a research chemical for human use.

The next phase of the compound's market presence will likely depend on the broader regulatory evolution of peptide therapy distribution in the United States. The compound itself is mature. The distribution channels are still in motion.

Footnotes

1. Palatin Technologies, public corporate history of the melanocortin receptor research program. SEC filings and published company materials. [verify specific reference]
2. Wessells H, Fuciarelli K, Hansen J, et al. "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study." J Urol. 1998;160(2):389-393. Early clinical observations of melanocortin agonists in sexual function. https://pubmed.ncbi.nlm.nih.gov/9679884/
   
3. Gantz I, Fong TM. "The melanocortin system." Am J Physiol Endocrinol Metab. 2003;284(3):E468-E474. https://pubmed.ncbi.nlm.nih.gov/12556347/
   
4. Pfaus JG, Sadiq A, Spana C, Clayton AH. "The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women." CNS Spectr. 2022;27(3):281-289. Review of the central mechanism of bremelanotide. https://pubmed.ncbi.nlm.nih.gov/33706838/ [verify]
5. FDA Vyleesi approval announcement, June 21, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women
   
6. Kingsberg SA, Clayton AH, Portman D, et al. "Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials." Obstet Gynecol. 2019;134(5):899-908. RECONNECT-1 and RECONNECT-2 trial results. https://pubmed.ncbi.nlm.nih.gov/31599840/
   
7. Vyleesi (bremelanotide injection) prescribing information. FDA-approved label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf [verify URL]
8. Diamond LE, Earle DC, Rosen RC, et al. "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction." Int J Impot Res. 2004;16(1):51-59. https://pubmed.ncbi.nlm.nih.gov/14963471/ [verify]
9. Federal Food, Drug, and Cosmetic Act, Section 503A. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act